Holocene Advisors’s GSK GSK Stock Holding History

Holocene Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,583,000	Closed	-$57.4M	–	754
2023 Q3	$57.4M	Buy	+1,583,000	New	+$56.2M	0.25%	123

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Holocene Advisors's GSK Position: Q2 2026 in Review

Holocene Advisors sold out of GSK (GSK) in Q2 2026, closing a stake of 5,518,433 shares — an estimated $305M sold.

Holocene Advisors first reported a position in GSK in Q2 2022 and held it in 14 quarters. The position peaked at $398M in Q4 2025. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Holocene Advisors reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
Holocene Advisors sold 5,518,433 GSK shares in Q2 2026, an estimated $305M.
Holocene Advisors first reported a position in GSK in Q2 2022 and held it in 14 quarters.
Holocene Advisors's GSK position peaked at $398M in Q4 2025.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.